Maximizing Adherence and Persistence via Patient Engagement
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Treatment Intensification in HR+/HER2- EBC: Who and When?
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.